Filing Details
- Accession Number:
- 0001725160-24-000032
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 19:14:48
- Reporting Period:
- 2024-02-01
- Accepted Time:
- 2024-02-05 19:14:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 823607803 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1863130 | Andrea Paul | C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway, Suite 801 New York NY 10018 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-01 | 112,500 | $0.00 | 153,283 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-02-02 | 3,310 | $11.54 | 149,973 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-02-01 | 112,500 | $0.00 | 112,500 | $11.69 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-02-01 | 90,000 | $0.00 | 90,000 | $11.69 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 112,500 | 2034-01-31 | No | 4 | A | Direct | |
| 90,000 | 2034-01-31 | No | 4 | A | Direct |
Footnotes
- Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Legal Officer, a role to which she was promoted on February 1, 2024.
- The options were granted to the Reporting Person in connection with Reporting Person's promotion to Chief Legal Officer, which became effective February 1, 2024. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.
Billionaire Hedge Funds
